SCHEMBL13264702

SCHEMBL13264702

CCOc1ccc(C(CC(=O)O)c2ccccc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 5/20 0.71
SMN1; SMN2 Q16637 3/20 0.58
CNR2 P34972 1/20 0.55
ALDH1A1 P00352 3/20 0.51
CYP2C9 P11712 2/20 0.51
CYP2C19 P33261 2/20 0.51
POLB P06746 2/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
GAA P10253 1/20 0.50
CYP2D6 P10635 1/20 0.50
LTA4H P09960 1/20 0.50
NPSR1 Q6W5P4 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
AKR1C3 P42330 1/20 0.48
AKR1C2 P52895 1/20 0.48
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2947981 0.87 SMN1; SMN2 (0.74) FFAR1SMN1; SMN2ALDH1A1CYP2C19POLB
SCHEMBL2948148 0.87 FFAR1 (0.68) FFAR1SMN1; SMN2ALDH1A1POLBLTA4H
SCHEMBL2949713 0.84 FFAR1 (0.77) FFAR1SMN1; SMN2ALDH1A1POLBL3MBTL1
SCHEMBL2941508 0.84 MMP9 (0.65) FFAR1SMN1; SMN2ALDH1A1POLBLTA4H
SCHEMBL2949131 0.83 MMP9 (0.67) FFAR1SMN1; SMN2POLBLTA4HL3MBTL1
SCHEMBL13236731 0.83 FFAR1 (1.00) FFAR1SMN1; SMN2ALDH1A1TSHR
SCHEMBL2946513 0.83 FFAR1 (1.00) FFAR1SMN1; SMN2ALDH1A1TSHR
SCHEMBL2939695 0.83 MMP9 (0.67) FFAR1SMN1; SMN2POLBLTA4HL3MBTL1
SCHEMBL13236734 0.83 FFAR1 (1.00) FFAR1SMN1; SMN2ALDH1A1TSHR
SCHEMBL28489153 0.83 FFAR1 (0.61) FFAR1CNR2CYP2C9CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115197036-B Method for performing anti-mahalanobis hydrogen carboxylation reaction on photocatalytic olefin compound and carbon dioxide 中国科学院理化技术研究所 2024-01-23 CN disclosed
CN-115197036-A Method for carrying out anti-Ma hydrocarboxylation reaction on olefin compound and carbon dioxide by photocatalysis 中国科学院理化技术研究所 2022-10-18 CN disclosed
US-7750048-B2 GPR40 agonists JANSSEN PHARMACEUTICA NV (BE) 2010-07-06 US disclosed
US-20080176912-A1 GPR40 AGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176912-A1 GPR40 AGONISTS GPR119, GPR65, GPR55 FFAR1 8/4885SMN1; SMN2 3652/4885CNR2 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.